Skip to main content
. 2023 Aug 11;15(16):4061. doi: 10.3390/cancers15164061

Figure 2.

Figure 2

Figure 2

HN analogue facilitates chemoresistance in human GBM cells. (A–E) U251-MG cells were incubated with different concentrations (A) or 1.25 μM HNGF6A (B–E) for 2 h before cisplatin (2 μM) was added for additional 72 h (n = six replicates/condition). Viability was assessed by the MTT assay (A,B), proliferation was evaluated by BrdU incorporation (ELISA) (C) and cell death was determined by the propidium iodide exclusion method (D). Representative dot plots are shown for each condition. (E) Clonogenic capacity was evaluated 10 days after seeding the cells that were alive after cisplatin treatment (n = three replicates/condition). The panels on the right show representative images of the colonies formed in each experimental condition at the end of the clonogenic assay. (F) mIDH glioma neurospheres derived from genetically engineered mouse tumors and patient-derived biopsies cells (G01) were incubated with HNGF6A (1.25 μM) for 2 h before adding cisplatin (5 μM) for 72 h. Viability was measured by MTT assay. * p < 0.05 vs. respective controls without HNGF6A; ^ p < 0.05 vs. respective control without cisplatin, ANOVA followed by Tukey’s test.